Partnering opportunity

UK-based SME offers novel small molecule for treatment of cancer

Summary

A UK-based SME has developed a novel small molecule that inhibits the Wnt cell signalling pathway that can lead to development of cancer. This molecule has been shown to have potent efficacy combined with excellent safety and is currently going though early clinical trials. The SME is looking to partner with other companies to take the molecule through clinical trials and into the clinic. The partnership is expected to be a licensing agreement or a technical cooperation.

Partner sought

The SME is looking to partner with other companies operating in the pharmaceutical sector, especially those developing therapies for cancer. The SME will offer it's porcupine inhibitor molecule to partners under licence for the partner to take through late stage clinical trials and to commercialisation. It is envisaged that the partnership will take the form of a licensing agreement. Technical cooperations will also be considered depending on circumstances.

Description

There are many cell signalling pathways than can lead to cancer developing. One of these is the Wnt pathway, which is implicated in tumour initiation, growth, cell senescence, cell death, differentiation and metastasis. There is also growing evidence that the Wnt pathway plays a role in the host immune response to tumours and that activation of the pathway may result in resistance to checkpoint inhibitors. Together this means that the Wnt pathway is an attractive target for new compounds aimed at the treatment of cancer. A UK-based SME has developed a novel small molecule that inhibits porcupine, a protein that initiates Wnt signalling. This molecule has the potential to benefit patients with cancers in which Wnt signalling is implicated, such as stonach, liver and pancreatic cancer. Testing on this molecule shows that it displays anti-proliferative activity in pre-clinical in vivo models, has a favourable pharmacokinetic profile in vitro and in vivo in pre-clinical species leading to an achievable predicted human efficacious dose following oral administration. Pre-clinical safety studies have been completed and MHRA approval gained for first-in-human clinical studies, with these studies currently underway. The SME is offering this molecule to companies operating in the pharmaceutical sector for further development, Phase 3, and commercialisation under license. It is expected that the cooperation will take the form of a licensing agreement, although technical cooperations will be considered depending on circumstances.

Advantages and innovations

The SME's novel small molecule has the following advantages: Potent efficacy demonstrated in mouse models. The molecule resulted in significant inhibition of tumour growth and tumour reduction compared with vehicle controls. The molecule improves the anti-tumour effect of anti PD-1 treatment in a mouse syngeneic model. Safety testing has shown no toxicity issues or adverse effects.

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Secret Know-how,Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company